Showing 3601-3610 of 9661 results for "".
- 2-Year ICONIC-LEAD Data Show Sustained Psoriasis Responses With Oral Icotrokinrahttps://practicaldermatology.com/news/2-year-iconic-lead-data-show-sustained-psoriasis-responses-with-oral-icotrokinra/2488701/Two-year findings from the Phase 3 ICONIC-LEAD trial showed sustained skin clearance and itch improvement with icotrokinra (ICOTYDE; Johnson & Johnson) in adults and adolescents aged 12 years or older with moderate-to-severe plaque psoriasis, according to data presented at the 2026 Fall Clini
- SYX-5219 Improves Eczema Severity, Itch in Early Clinical Trialhttps://practicaldermatology.com/news/syx-5219-improves-eczema-severity-itch-in-early-clinical-trial/2488689/An investigational oral therapy targeting immune cell metabolism demonstrated improvements in disease severity and itch among adults with moderate to severe atopic dermatitis (AD), according to Phase 1b results announced by Sitryx Therapeutics. SYX-5219, a first-in-class pyruvate kinase M2
- Envudeucitinib Improves Itch by Week 2 in Phase 3 Plaque Psoriasis Trialshttps://practicaldermatology.com/news/envudeucitinib-improves-itch-by-week-2-in-phase-3-plaque-psoriasis-trials/2488683/Investigational oral tyrosine kinase 2 (TYK2) inhibitor envudeucitinib produced clinically meaningful itch improvement as early as week 2 in patients with moderate-to-severe plaque psoriasis, according to 24-week results from the phase 3 ONWARD1 and ONWARD2 trials. Jason E. Hawkes, MD, and
- TOGETHER-PsO: Combination Therapy Shows Expanded Molecular Response by Week 12https://practicaldermatology.com/news/together-pso-combination-therapy-shows-expanded-molecular-response-by-week-12/2488671/Eli Lilly and Company announced Phase 3 data from the TOGETHER-PsO trial indicating broader immune and metabolic biomarker changes with concomitant ixekizumab (Taltz) and tirzepatide (Zepbound) compared with ixekizumab alone in adults with moderate-to-severe plaque psoriasis and obesity or overwe
- Telehealth Intervention Improves Sun Protection Behaviors in Children of Melanoma Survivorshttps://practicaldermatology.com/news/telehealth-intervention-improves-sun-protection-behaviors-in-children-of-melanoma-survivors/2488649/A family-based telehealth intervention significantly improved sun-protective behaviors among children of melanoma survivors but failed to reduce sunburn over time, according to findings from a randomized study published in JAMA Dermatology. Thye study sought to evaluate whether th
- Sun Pharma Establishes $2.5 Million Dermatology Professorship at Mount Sinaihttps://practicaldermatology.com/news/sun-pharma-establishes-25-million-dermatology-professorship-at-mount-sinai/2488636/Sun Pharma has established an endowed dermatology professorship at the Icahn School of Medicine at Mount Sinai, naming longtime psoriasis researcher and academic dermatologist Mark G. Lebwohl, MD, as its inaugural holder. Supported by a $2.5 million endowment from Sun Pharma, the Sun Profe
- International Consortium of Mohs Surgery Launches to Support Global Collaboration in Skin Cancer Carehttps://practicaldermatology.com/news/international-consortium-of-mohs-surgery-launches-to-support-global-collaboration-in-skin-cancer-care/2488635/The International Consortium of Mohs Surgery (ICMS) has officially launched as a global professional association focused on advancing Mohs micrographic surgery and cutaneous oncology through education, research, collaboration, and professional exchange. ICMS leadership signed the organizat
- Zasocitinib Outperforms Deucravacitinib in Phase 3 Head-to-Head Psoriasis Trialhttps://practicaldermatology.com/news/zasocitinib-outperforms-deucravacitinib-in-phase-3-head-to-head-psoriasis-trial/2488633/Investigational oral tyrosine kinase 2 (TYK2) inhibitor zasocitinib (TAK-279) demonstrated superior skin clearance compared with deucravacitinib in adults with moderate-to-severe plaque psoriasis, according to phase 3 data presented at the European Academy of Dermatology & Venereology (EADV)
- Short-Course Vunakizumab Shows Rapid Improvement in Pediatric GPPhttps://practicaldermatology.com/news/short-course-vunakizumab-shows-rapid-improvement-in-pediatric-generalized-pustular-psoriasis/2488622/Short-course treatment with vunakizumab was temporally associated with rapid improvement of acute generalized pustular psoriasis (GPP) flares in 3 pediatric patients, according to a case series published in Frontiers in Immunology. Vunakizumab Treatment in Pediatric GPP Flares
- Litifilimab Meets Primary Endpoint in Phase 2 Cutaneous Lupus Studyhttps://practicaldermatology.com/news/litifilimab-meets-primary-endpoint-in-phase-2-cutaneous-lupus-study/2488613/Biogen reported positive phase 2 results from Part A of the phase 2/3 AMETHYST study evaluating litifilimab in patients with cutaneous lupus erythematosus (CLE), with the investigational therapy meeting the study’s primary endpoint and showing improvement across several mea